Radioimmunotherapy of micrometastases in lung with vascular targeted213Bi by Kennel, S J et al.
Therapy of solid tumours using targeting agents such as tumour
cell-directed monoclonal antibodies (mAbs) has proven to be diffi-
cult due to the relatively low fraction of the total dose delivered
specifically to the tumour. It has been postulated for some time
(Denekamp, 1984) that the tumour blood vessels are more acces-
sible targets for directed therapy. Recent work has shown that
agents which interfere with new blood vessel formation (angio-
genesis) are capable of inhibiting tumour growth in experimental
animals (Kim et al, 1993; O’Reilly et al, 1995, 1997; Borgström et
al, 1996). The drawback of this approach is that once treatment is
stopped, the tumours grow rapidly and eventually prove fatal.
Another approach utilized immunotoxins specific for tumour
blood vessels. In a model system, an immunotoxin, targeted to
major histocompatability complex components induced in blood
vessels through genetically altered tumour cells, proved to be
therapeutic (Burrows and Thorpe, 1994) and infarction and cure
of tumours was observed.
For therapy of small metastases, it is desirable to destroy both
the tumour blood vessels and the tumour cells. In this work, short-
range, high linear energy transfer (LET) radiation (213Bi) was
targeted to blood vessels feeding tumours in the lung. The mAb
used, mAb 201B, binds to murine thrombomodulin (TM). TM is
expressed selectively and in large amounts on the lumenal surfaces
of capillaries and small blood vessels in the lung. mAb 201B
injected intravenously (i.v.) localizes quickly and in high concen-
tration in murine lung (Kennel et al, 1990). This system was used
previously to target the b-particle emitter 131I to lungs bearing
tumours, resulting in a marginal therapeutic effect (Blumenthal et
al, 1992). The localization characteristics of mAb 201B allow
targeting of short half-lived isotopes such as the a-particle emitter
213Bi (t1/2 = 45 min), with delivery of a large fraction of the
absorbed dose to the lung as a target (Kennel and Mirzadeh, 1997).
The model of experimental lung tumour colonies has been used to
test the efficiency of vascular-targeted 213Bi for radioimmuno-
therapy. In this system, tumour cells injected i.v. lodge in the lung
and form colonies. mAb 201B is then used to deliver 213Bi to all
the lung vessels, including those which feed the tumour colonies.
The tissue range of the 213Bi a-particle is 60–100 m and thus
should produce damage not only to lung vessels, but also to the
tumour cells adjacent to the vessels. A preliminary paper has
shown that high-dose therapy resulted in tumour cures, but that
collateral lung damage occurred (Kennel and Mirzadeh, 1998).
Dose–response experiments and radioimmunotherapy with
different tumour types were necessary to assess the limits of effec-
tiveness of this approach. We show herein that lung tumour
colonies can be significantly reduced by this treatment in five
different tumour types with relatively low doses of radioisotope
and that tumours which are immunogenic in the host can be cured
completely.
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Summary A model system has been used to test the efficacy of vascular targeting of a-particle emitter 213Bi for therapy of small, ‘artificial’
metastases in mouse lung. Specific monoclonal antibody (mAb) 201B was used to deliver greater than 30% of the injected dose to lung where
tumours had developed due to intravenous injection of cells. Specific 213Bi-mAb 201B treatment of BALB/c mammary carcinoma EMT-6
tumours in lung resulted in a dose-dependent destruction of tumours and an extended lifespan of treated animals relative to controls.
Significant reduction of lung tumour burden was noted in animals treated with 0.93 MBq injected dose or as little as 14 Gy absorbed dose to
the lung. Animals treated with higher doses (2.6–6.7 MBq) had nearly complete cure of lung tumours but eventually died of lung fibrosis
induced by the treatment. Four other tumour cell types were studied: murine Line 1 lung carcinomas in syngeneic BALB/c mice, rat IC-12
tracheal carcinoma growing in severe combined immune deficient (SCID) mice, and two human tumours – epidermoid carcinoma A431 and
lung carcinoma A549 – growing in SCID mice. In all cases, the number of lung tumour colonies was reduced in animals treated with specific,
labelled mAb relative to those in animals treated with control 213Bi MAb or EDTA complexed 213Bi. Tumours treated in immunodeficient SCID
mice were partially destroyed or at least retarded in growth, but ultimately regrew and proved fatal, indicating that an intact immune function
is necessary for complete cure. The data show that the short-lived a-particle emitter 213Bi can be effectively targeted to lung blood vessels and
that tumour cells growing in the lung are killed. The mechanism may involve direct killing of tumour cells from a-particle irradiation, killing
through destruction of blood supply to the tumour, or a combination of the two.
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Cells and animals
EMT-6 cells were derived from a BALB/c mammary carcinoma
(Rockwell et al, 1972). They were cultured in Dulbecco’s
Modified Eagle Medium (DMEM) containing 10% fetal bovine
serum (FBS) and were used at passage 8–12. Tumour-derived
BALB/c Line 1 lung adenocarcinoma cells (Yuhas et al, 1975)
designated 498 were developed at ORNL. The cells were cultured
in DMEM with 10% FBS. Cells were used at passage 12–22. Both
cells lines were tested repeatedly for mycoplasma contamination
using a DNA probe (Gen-Probe, Inc., San Diego, CA, USA).
IC-12 rat tracheal carcinoma was derived from an F344 rat
undifferentiated carcinoma induced in vivo in a trachea by expo-
sure to DMBA (Terzaghi-Howe, 1987). It was cultured in B1
modified Ham’s F12 medium and used at passage 33.
A431 squamous cell carcinoma and A549 lung adenocarcinoma
(Giard et al, 1973) were derived from human tumours. The cell
lines were obtained from the American Type Culture Collection.
A431, cultured in McCoy’s 5A medium with 10% FBS, and A549,
cultured in F12K medium with 15% FBS, were used at passages
34 and 52 respectively.
BALB/c and ICR severe combined immune deficient (SCID)
mice were bred in the ORNL barrier facility and maintained in a
specific pathogen-free (SPF) environment in the AAALAC
approved facility. Experiments were completed under the institu-
tional animal care and use committee approved protocol 0138.
mAb and radioisotope
mAb 201B to mouse TM, a rat IgG2a, and control rat mAb 14 have
been described previously (Kennel et al, 1988). mAb 14 was derived
from a rat–mouse hybridoma. It has no known binding specificity
either in animals or for any tissue culture cells tested. Purified mAb
was derivatized with cyclohexyl diethylenetriaminepentaacetic acid
(CHXb-DTPA; Brechbiel and Gansow, 1992), kindly provided by
Dr Brechbiel (NIH, Bethesda, MD, USA), at an average of 1–2
176 SJ Kennel et al
British Journal of Cancer (1999) 80(1/2), 175–184 © Cancer Research Campaign 1999
Table 1 Tissue distribution and dosimetry of 213Bi–mAba
1h 2h 3h 6h ab Cross dose to lung
mAb 201 (specific) % ID per g Total dose delivered Gy/MBq
Blood 1.85 ± 0.07 0.73 ± 0.1 ~0.4 – – – –
Muscle 0.72 ± 0.01 0.65 ± 0.13 0.46 ± 0.1 – – – 0.0012
Liver 14.0 ± 0.56 16.2 ± 1.9 16.5 ± 3.8 14.8 ± 0.9 0.85 0.044 0.0047
Spleen 14.8 ± 1.5 20.8 ± 1.8 19.1 ± 0.4 24.6 ± 2.3 0.63 – –
Kidney 34 ± 0.8 36.7 ± 3.2 18.1 ± 1.0 18.8 ± 1.5 1.4 0.055 < 0.001
Lung 237 ± 24 204 ± 19.5 235 ± 22 210 ± 13 15.5 0.30 –
mAb 14 (control) % ID per g Total dose delivered by Gy/MBq
Blood 16.3 ± 3.5 16.4 ± 1.1 15.3 ± 1.4 – – – –
Muscle 0.87 ± 0.02 0.88 ± 0.01 0.52 ± 0.01 – – – 0.0010
Liver 40.3 ± 0.7 41 ± 4.2 36.1 ± 1.1 33.6 ± 2.8 2.26 0.012 0.0012
Spleen 7.95 ± 0.4 7.2 ± 0.7 6.9 ± 0.2 6.0 ± 1.8 0.40 – –
Kidney 19.1 ± 0.5 19.5 ± 0.2 12.2 ± 0.8 12.0 ± 0.14 0.83 0.003 < 0.001
Lung 7.1 ± 0.2 8.4 ± 1.9 5.4 ± 0.5 4.5 ± 0.1 0.50 0.010 –
aFor each time point, BALB/c mice, injected i.v. 6 days previously with 2 ´ 104 EMT-6 tumour cells, were injected with 4.1 MBq 213Bi on 14 mg of either mAb 201B
or control mAb 14. Chelation efficiency ranged from 86 to 91% and the preparations were injected after dilution from the chelation reaction without further
purification.
Table 2 Dose–response for treatment of EMT-6 tumours in BALB/c mice
Treatmenta Lung tumours
mAb mg 213Bi (mBq) Animals with tumours Tumours per lungb
number treated
201B 33 0 8/8 78.3 ± 10
201B 4 0.925 5/7 12 ± 5
201B 8 2.6 1/7 13
201B 4/11/7 1.0/1.0/1.0 7/7 2 (> 200)
5 (14 ± 8)
201B 16 3.33 0/8 –
201B 33 6.7 0/7 –
14 20 4.3 3/7 30 ± 8
14 40 7.0 0/7 –
aBALB/c Bd l l + mice were injected i.v. with 4 ´ 104 EMT-6 (passage 8) cells. Animals were treated 5 days after cell injection with i.v. injection of
the labelled mAb in 200 ml MES. The fractionated doses were given at 3-day intervals. bAverage number ± s.d. of tumours counted in
histology sections from lungs of tumour-positive animals (Experiment 25 October 1996).Vascular targeted radioimmunotherapy 177
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Figure 1 Time course of EMT-6 tumour treatment in BALB/c lung. BALB/c Bd 8-week-old female mice were injected i.v. with 2 ´ 104 EMT-6 cells passage 10.
Five days later they were injected i.v. with 24 mg (4.3 MBq) of 213Bi–mAb 201B (A, C, E and G, or with 24 mg mAb 201B with no 213Bi (B, D, F and H). Animals
were sacrificed and their lungs inflated for histology at 4 h (A, B); 1 day (C, D) 3 days (E, F) and 7 days (G, H). Representative tumour sites were video
captured and processed using Adobe Photoshop. Approximate magnification 100´chelator molecules for each mAb (Kennel and Mirzadeh, 1997).
213Bi was eluted from an 225Ac generator (Boll et al, 1997) in 300 ml
of 0.15 M HI, neutralized with 3 M NaAc and reacted with 50–
200 mg-derivatized mAb for 6 min, followed by addition of 2 ml of
0.2 M EDTA. The product was diluted in 2-(N-morpholina) ethane
sulforic acid (MES) buffer, tested for extent of radiolabelling by use
of a Microcon 30 centrifugation filter and injected without purifica-
tion into animal tail veins in 200 m1 volumes. Radiolabel incorpora-
tion ranged from 80 to 90%.
Isotope distribution studies in animals with tumours were done
essentially as described previously (Hughes et al, 1989). Standard
samples were counted in an automatic g-counter (440 KeV, g) with
the test tissue samples. Corrections were made for isotope decay
using  t1/2 = 45 min. For dosimetry calculations, kinetic data
gathered from animals were fitted to one- or two-compartment
exponential functions using the SAAM II software (Foster and
Barrett, 1997). The resultant time–activity curves were integrated
to obtain organ residence times (Loevinger et al, 1988) for 213Bi
(and daughters). S-values were developed for a 30 g mouse using
the MCNP radiation transport software (Briemeister, 1993;
Yoriyaz and Stabin, 1997). The mouse model was primarily used
to obtain electron self-and cross-doses. a-particle radiation was
assumed to be 100% locally absorbed and photon doses were not
considered significant, as they represented <1% of the total dose.
Animal studies
Cells were recovered from frozen storage and passaged once
before harvest. Plated cells were harvested when 80% confluent by
treatment with trypsin–EDTA. Cells were washed from the plates
in growth medium containing FBS to neutralize residual trypsin,
counted in a haemocytometer, collected by centrifugation and
diluted to the appropriate concentration (see Table legends) in
PBS. All cells were injected in 200 ml volumes i.v. in a tail vein
using a 27-gauge needle within 30 min of harvest.
At designated times, chelated mAbs were prepared, checked for
radiolabelling efficiency, quantitated by monitoring the g-ray
emission in a well-type Na(Tl) gamma detector, diluted to the
appropriate concentration without purification and injected i.v. in
200 ml MES. Treated animals were housed in a designated radia-
tion area for 1 day and then transferred to a regulated SPF barrier
room. Animals were observed daily and sacrificed when moribund
or when external tumours exceeded 1 cm3 in volume.
Necropsy was performed on animals sacrificed by cervical
disarticulation. Neutral buffered formalin (0.6 ml) was instilled
into the lung through a tracheal catheter and the trachea ligated
with standard cotton thread. Organ samples and the heart–lung
block were fixed by submersion in buffered formalin for 24 h.
Each pulmonary lobe was embedded separately. Lobes were cut
along the longitudinal axis of their bronchi and the resulting two
halves were embedded face down in paraffin. Sections of 5 mM
were cut from blocks trimmed to give maximum tissue cross-
section exposure and then stained with haematoxylin and eosin.
Lung tumours in a single section per animal were enumerated in a
‘double blind’ fashion using a dissecting microscope.
RESULTS
Distribution and dosimetry
We have shown previously that iodinated mAb 201B accumulates
in the lung rapidly, resulting in a large fraction of the total dose (up
to 50%) accumulating within 5 min post injection (Hughes et al,
1989). For experiments on treatment of lung colonies (artificial
metastases), the distribution of 213Bi–mAb 201B and that of
control mAb 14 have been determined as a function of time in
mice bearing EMT-6 tumours. Data in Table 1 show that even if
the chelation mixture is used without purification, about 33% of
the injected dose of 213Bi is delivered to lung (> 200% ID per g)
and this fraction remains essentially constant from 1 to 6 h post
injection. In contrast, control mAb 14 delivers about 1% of the
dose to lung (< 10% ID perg). 213Bi that is not attached to mAb is
rapidly cleared from the circulation (< 1 h) and eliminated in the
urine (Kennel and Mirzadeh, 1997).
Decay of 213Bi is 98% b-particle (0.41 MeV average) to 213Po
and 2% a (5.8 MeV) to 209Tl. 213Po (t1/2 = 4 ms) decays by a-
particle (8.3 MeV) to 209Pb. 209Pb was released by the chelator and
decays by b-particle (0.214 MeV average) to stable 209Bi. 213Bi
decay emits a 440 KeV g (26%). Dosimetry calculations were
done to determine the direct dose of a-particle plus b-particle irra-
diation to the lung and the ‘cross-dose’ of b-particles to the lung
from other organs. The model utilized the time activity data of
Table 1 and a specific exponential retention function to estimate
the residence times of the 213Bi in each organ. As expected, the
absorbed dose of a-particle irradiation delivered to the lung by
mAb 201B was more than tenfold higher than for any other organ,
and was 30-fold higher than that delivered to the lung by control
mAb 14. The absorbed dose of b-particle irradiation delivered to
the lung from 213Bi–mAb 201B was due predominantly to 213Bi in
the lung with little (< 5%) cross-irradiation contributed from the
liver or other nearby organs. Overall, the total b-particle dose was
50-fold less than the a-particle dose. The b-particle dose from
213Bi–mab 14 had a total cross-irradiation component to the lung of
about 20%, but the total dose to the lung from this control mAb
was less than 5% of that delivered by the specific MAb. Thus, the
data show that a-particle irradiation from the specific mAb was by
far the dominant factor in absorbed dose to the lung. The microdis-
tribution of a-particle irradiation is also important. Previous work
has shown that mAb 201 binds uniformly to the lung endothelium
(Kennel et al, 1990) and thus would be expected to deliver the
majority of absorbed dose within 60–100 m of this position. The
position of the capillaries in alveolar septa relative to the tumours
can be seen in Figure 1. An autoradiographic photomicrograph of
the position of mAb 201B relative to the tumour cells has been
published (Mori et al, 1995).
Treatment of EMT-6 tumours
When injected i.v., the majority of EMT-6 cells lodged in the lung,
and some formed lung colonies in perivascular areas and in the alve-
olar parenchyma (Figure 1). The cell dose used resulted in about 100
colonies per lung which, when left untreated, killed the mice within
13–20 days post-injection. A fraction (10–20%) of the animals
cured of lung tumours (see below) developed tumours at later times
at sites outside the lung – primarily at subcutaneous (s.c.) sites in the
extremities. These animals were sacrificed as tumours approached 1
g in size (30–60 days post-injection). The remaining animals, cured
of tumours, developed lung disease that was fatal starting at day 80
onward. All animals in the study were examined by gross necropsy
and histology to help determine the cause of death.
Several experiments were done to test the therapeutic effect of
213Bi–mAb 201B on EMT-6 tumours resulting from i.v. injection.
Dose–response data in Table 2 show that two of seven animals
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lung tumours. Animals not cured at this dose had fewer lung
tumours (12 ± 5 v 78 ± 10 in control animals treated with unla-
belled mAb 201B) and died later (33 days ± 12 days) than control
animals (14.3 days ± 1.7 days). A dose of 2.6 MBq cured all but
one of seven animals and extended lifespan to 98 days ± 56 days.
Doses of 3.33 and 6.7 MBq on specific mAb 201B completely
eradicated the lung tumour colonies in this experiment. The time
to sacrifice in these groups was: 3.33 MBq, 86 days ± 39 days;
6.7 MBq, 50 days ± 26 days. A total dose administered as three
Vascular targeted radioimmunotherapy 179
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Table 3 Fractionated dose treatment of EMT-6 tumours in BALB/c mice
Treatmenta Lung tumours Time to sacrificec
Group MAb mg 213Bi (MBq) Animals with Tumours per (days ± s.d.)
tumours/number lungb
treated
1 201B 8 0 7/7 99 ± 13 13.8 ± 0.7
2 201B 12 2.44 0/7 – 97 ± 41
3 14 12 2.29 6/7 96 ± 103 28 ± 8
4 201B 6/10/11 1.0/0.7/1.0 6/7 13 ± 6 39 ± 39
5 14 7/10/11 1.0/0.7/1.0 7/7 129 ± 55 16 ± 1.3
6 201B 22 4.3 1/7 150 100 ± 39
7 201B 11/10/11 2.4/1.7/1.7 6/7 7 ± 7 50 ± 20
aBALB/c l l + mice from Taconic Farms were injected i.v. with 4 ´ 104 EMT-6 (passage 12) cells. Animals were treated with 213Bi–mAb at day 5. Dose fractions were
given at 3-day intervals. bSignificance levels for lung tumour numbers: specific mAb efficacy group 4 vs group 5, P ~ 0.001 (Experiment 7 January 1997)
cSignificance levels for time to sacrifice: labelled mAb therapy: groups 2, 6 and 7 all vs group 1; P < 0.001; split dose analyses: group 2 vs group 4, P ~ 0.001;
group 6 vs group 7, P ~ 0.01. specific mAb therapy: group 2 vs group 3, P = 0.018; group 4 vs group 5, P ~ 0.01.
Table 4 Treatment of EMT-6 tumours in C3H SCID mice
Treatmenta Lung tumoursc Time to sacrificed
Group mAb mg 213Bi (MBq) Number Tumours per (days ± s.d.)
positive/tested lung
1 201B 8 3.0 5/5 7.2 ± 4.3 25 ± 4
2 14 21 2.6 5/5 88.6 ± 37 17.8 ± 1.3
3 201Bb 8 3.0 4/4 111 ± 25 15.8 ± 0.5
EDTA
4 201B 8 2.6 – – 83 ± 14
aC3H-SCID mice injected i.v. with 2 ´ 104 EMT-6 cells (passage 14) except for group 4. Animals were treated 5 days later with i.v. injections of 213Bi-mAb. b213Bi
mixed with EDTA and mAb to prevent coupling of the mAb with the isotope. cSignificance levels: group 1 vs group 2; P ~ 0.001; group 1 vs group 3, P < 0.001.
dSignificance levels group 1 vs group 2, P = 0.003; group 1 vs group 3, P ~ 0.001 (Experiment 10 April 1997).
Table 5 Treatment of Line 1 lung carcinoma in BALB/c mice
Treatmenta
Group mAb mg 213Bi (MBq) Day treated Animals Tumours per lung ± s.d.b
Experiment 1
1 201B 40 6.0 6 10 20 ± 15
2 14 40 5.4 6 10 35 ± 10
Experiment 25
3 201B 22 4.9 5 5 13 ± 8
4 14 22 4.9 5 4 55 ± 11
5 201B 22 4.9 6 5 25 ± 10
Experiment 3
6 201B 13 3.7 5 9 11 ± 8
7 14 14 3.7 5 10 43 ± 15
8 201B(EDTA) 12 3.9 5 10 61 ± 26
aBALB/c l l + mice injected i.v. with 1 ´ 105 Line 1 cells (passage 12) (Experiment 1, 30 October 1996); 2 ´ 105 Line 1 cells (passage 22) (Experiment 2, 14
November 19); 1 ´ 105 Line 1 cells (passage 18) (Experiment 3, 10 January 1997). bSignificance levels for specific mAb to controls. Group 1 vs group 2,
P = 0.025; group 3 vs group 4, P < 0.001; group 6 vs group 7 and group 4 vs group 5,P = 0.003; group 6 vs group 8, P < 0.001.180 SJ Kennel et al
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Figure 2 Photomicrographs of lung sections from treated and control SCID mice which had been injected with IC-12 rat carcinoma. Seven-week-old ICR SCID
male mice were injected i.v. with 1 ´ 106 IC-12 cells. Individual animals were treated at day 7 with 20 mg (3.0 MBq) of 213Bi–mAb 201B (A 1–5); 20 mg (2.7 MBq)
213Bi–mAb 14 (B) or 20 mg unlabelled mAb 201B (C). Animals were sacrificed when moribund (A 47 ± 7 days; B, 19.4 ± 3 days; C, 14.8 ± 0.8 days) and lungs
were processed for histology. Approximate magnification = 2´fractions of 213Bi–mAb 201B did not kill the lung tumours as well
as did a single dose.
The histologic appearance of lungs of animals in these treatment
groups is shown in Figure 1. Most tumours grew perivascularly
(although some grew in the parenchyma) and were therefore good
targets for a-particle-mediated therapy. Representative areas of
lung sections from animals 5 days after i.v. injection with EMT-6
cells are shown, either treated with radiolabelled mAb 201B
(Figure 1 A, C, E, G) or unlabelled MAb 201B controls (Figure 1
B, D, F, H). Each animal had about 100 tumours in the evaluated
sections (see Methods for histology sampling) of about 10–50 cells
in cross-section. Each tumour contained 150–1500 cells at the time
of treatment. At 4 h post-treatment, no differences in tumour
morphology were noted (Figure 1 A vs B). At this time the tumour
colonies were of only microscopic size, consisting of one or two
cell layers. At 24 h, the 213Bi-treated animals demonstrated cyto-
plasmic swelling of tumour cells and an apparent arrest in tumour
growth (Figure 1C), whereas the control tumours had developed
into colonies comprised of several cell layers (Figure 1D). By day
3, the tumour colonies in the animals given 213Bi were necrotic
(Figure 1E), whereas the tumours in mice treated with unlabelled
mAb 201B had continued to grow (Figure 1F). Tumours in the
control group continued to grow and, by day 7 (Figure 1H), occu-
pied a significant proportion of the lung. This resulted in laboured
breathing and the animals were sacrificed. By contrast, the lungs
of treated animals were essentially tumour free at this time with
scattered focal areas of cellular debris (Figure 1G). Staining for
apoptotic cells in these sections, treated as well as untreated
animals, remained constant at 2–5% of tumour cells, although cells
in spleens of treated animals showed a dramatic, dose-dependent
increase in staining for apoptotic cells (data not shown). An unex-
pected result in this experiment was that 213Bi control mAb 14 had
a significant therapeutic effect especially at high dosage (see
Discussion).
As reported earlier (Kennel et al, 1998), animals cured of
tumours by treatment with 213Bi–mAb 201B developed lung
disease later in life. Animals treated with 2.6 MBq develop lung
disease at about 130 days; 3.33 MBq at 110 days; and 6.7 MBq at
85 days. Fractionated doses of labelled mAb were given to attempt
to alleviate this complication. Data in Table 3 (and Table 2) show
that fractionated doses of labelled mAb were less effective in
tumour therapy than single doses (Table 3, group 2 vs group 4; and
group 6 vs group 7). Survival times of specific 213Bi–mAb 201B-
treated animals were all significantly longer than those treated
with control 213Bi–mAb 14 at comparable injected doses (group 2
vs group 3, P = 0.1) and (group 4 vs group 5, P = 0.01). It should
be noted that the time to sacrifice presented here includes death
due to lung tumours, s.c. tumours and pulmonary fibrosis.
Numbers of tumour colonies per lung, although quite variable in
treated animals, were significantly reduced when values for
specific mAb groups were compared to those for controls (group 2
vs group 3, P = 0.018; group 4 vs group 5, P = 0.001).
To determine if immune competence of the animals was neces-
sary for tumour cures, an experiment was done with EMT-6 cells
injected into C3H SCID mice. Data in Table 4 show that mice
treated with 213Bi–mAb 201B (group 1) lived significantly longer
and had fewer lung tumours than mice treated with 213Bi–mAb 14
(group 2) or 213Bi–EDTA mixed with, but not chelated to, mAb
201B (group 3), even though all animals eventually died of lung
tumour burden.
Treatment of Line 1 carcinomas
Similar to the EMT-6 tumour cells, BALB/c Line 1 lung carci-
noma cells injected i.v. lodged primarily in the lung. Lung colonies
were more nodular and avascular than for EMT-6 tumours and, as
such, represented a poorer target for vascular-targeted radioi-
sotope. Line 1 cells are very malignant and do not induce a
detectable immune response in the syngeneic host. This cell
system is a good model for study of treatment of avascular, non-
immunogenic tumours; however, i.v. injection resulted in many
extrapulmonary tumours. While only a small fraction of EMT-6-
injected animals developed tumours outside of the lung, virtually
all of the animals injected i.v. with Line 1 cells developed tumours
in the heart muscle or chest wall in addition to their lung tumours.
The heart tumours proved fatal early after injection (15–20 days)
and they could not be cured in the model system which localized
213Bi–mAb 201B in the lung. Consequently, all the animals tested
in the Line 1 system died of heart/chest tumours. However, at the
time of sacrifice, the numbers of tumours in the lung were signifi-
cantly reduced by treatment with specific 213Bi–mAb 201B (Table
5). The three experiments reported all showed significant
decreases of lung tumours in animals treated with 213Bi–mAb 201B
versus those treated with 213Bi–mAb 14, even if the treatment was
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Table 6 Treatment of human carcinomas in ICR SCID mice
Day of Number
mAb mg 213Bi (MBq) treatment positive/tested Tumours per lungc
Treatmenta of A431 tumours Lung tumours
1 201B 13 2.8 11 10/10 19 ± 10
2 14 13 2.8 11 10/10 126 ± 53
3 – – 0 – 4/4 127 ± 85
Treatmentb of A549 tumours Lung tumours
4 201B 13 2.8 10 4/6 4.5 ± 6d
5 14 13 2.8 10 5/6 55 ± 83
6 201B (EDTA) 13 2.8 10 5/5 86 ± 72
aICR SCID mice injected with 7.5 ´ 105 A431 cells (passage 34) (Experiment 6 January 1997). bICR SCID mice injected with 106 A549 cells (passage 52)
(Experiment 10 January 1997). cGroup 1 vs group 2, P < 0.001 (significant); group 4 vs group 5, NS; group 4 vs group 6, P = 0.037. dTumour lesions
haemorrhagic but still contain viable tumour cells.delayed 1 day (to day 6) when tumours were larger. Treatment
at day 5 (smaller tumours) was superior to treatment of larger
tumours (day 6). However, none of the treated animals were totally
cured of lung tumours.
Treatment of IC-12 rat tracheal carcinomas
IC-12 cells injected in SCID mice grew perivascularly in a pattern
similar to that for EMT-6 cells. ICR SCID mice injected i.v. with
IC-12 cells were treated on day 7 with 2.7–3.0 MBq 213Bi coupled
to 20 mg mAb 201B or MAb 14. Low power magnification
photomicrographs of the histological sections of lung are shown in
Figure 2. The growth pattern of IC-12 cells along blood vessels
made it impossible to quantitate actual lung colonies in control
animals; however, animals treated with the specific 213Bi–mAb
201B had a lower tumour burden at sacrifice than did controls.
Tumours in treated animals appeared larger, because these animals
were sacrificed later than those in the control groups. Animals
treated with 213Bi–mAb 201B (Figure 2A1–5) had a significantly
longer lifespan (47 ± 7 days) compared to those treated with
213Bi–mAb 14 (Figure 2B1–5) (19.3 days ± 3 days) or those treated
with unlabelled mAb 201B (Figure 2 C1–5) (14.8 days ± 0.8
days). This result was comparable to that for treatment of EMT-6
tumours in immunodeficient C3H SCID mice (Table 4).
Treatment of human tumours in SCID mice
Eight human tumour lines were tested for their growth in SCID
mice lungs after i.v. injection. Two, A549 and A431, grew as lung
colonies at low frequency. Tumour cells of human origin grew
much more slowly than rodent tumours. A431 grew as an avas-
cular nodule with the interior cells forming and secreting keratin to
the tumour centre as the tumour size increased. Many of the
animals developed extrapulmonary tumours and had to be sacri-
ficed. The time to sacrifice was not significantly lengthened by
treatment with 213Bi–mAb 201B. However, histologic examination
showed that animals treated with specific 213Bi–mAb 201B had
fewer lung tumours than those treated with control 213Bi–mAb 14
(Table 6).
A549 was derived from a human lung adenocarcinoma.
Intravenous injection of tumour cells resulted in lung colonies in
the majority of animals. As for A431, treatment with 213Bi–mAb
201B did not extend the lifespan of animals, but did result in fewer
lung tumours (Table 6). Due to tumour number variability, the
differences were marginally statistically significant. Many
tumours in animals treated with specific antibody were haemor-
rhagic (data not shown).
DISCUSSION
Previous work with a-particle emitters has been done with
lymphoid tumours which are accessible to the circulation (Huneke
et al, 1992; Hartmann et al, 1994) or with injections of radio-
labelled mAb directly to the tumour site (Zalutsky et al, 1994).
Since the short-range, high LET a-particle should be useful for
local destruction of tumour cells, we devised a model whereby the
a-particle emitter was targeted to blood vessels feeding micro-
metastatic tumours in the lungs.
The present system relies on the targeting of isotopes to normal
blood vessels. The specific mAb 201B that reacts with murine
TM has been shown to bind efficiently to the lumenal side of
endothelial cells lining capillaries and vessels in the lung (Hughes
et al, 1989; Kennel et al, 1990). Knowledge of the positioning of
the isotope relative to the tumour cells is an advantage in inter-
preting the results. The radiation dose calculations indicate that
most of the lung dose comes from a-particle self-dose, with a
much smaller contribution from the lung bound 213Bi b-particle
emission and even less from b-particle cross-dose to the lung from
other organs. A more complete description of the dosimetry would
be obtained by performing an analysis of the microdosimetry.
Humm et al (1987) calculated the absorbed dose to cell nuclei
from 211At positioned in a central capillary. He concluded that,
even at very large doses, about 40% of the tumour cells were too
far from the source to get a lethal hit. The tumours observed in this
study were rather well dispersed throughout the lung, and most
were perivascular in origin with cells within about 50 m from the
nearest vessel. Thus, the macrodosimetric estimates shown in
Table 1 may be more valid than in some other cases involving
therapy with a-particle emitters.
The data show that high doses of 213Bi–mAb 201B completely
eradicated EMT-6 tumours in lungs. High doses of 213Bi–mAb 14
also had a therapeutic effect in the EMT-6 system at about fivefold
higher doses (Tables 2 and 3). 213Bi complexed with EDTA and
mixed with mAb 201B had no significant effect (data not shown).
Dosimetry calculations indicate that per input activity mAb 14
should deliver about 30-fold less a-particle dose to the lungs than
does mAb 201B. The long circulation times of 213Bi–mAb 14
relative to that of 213Bi complexed to EDTA may alter the blood
chemistry; however, we have no other plausible explanation for
the effect.
The mechanism of tumour eradication is not clear. Photo-
micrographs in Figure 1 in conjunction with stains for apoptotic
cells indicate that EMT-6 cells die between day 1 and 3 and
undergo necrosis, but not apoptosis. Debris was cleared over the
next week, but areas of the lung where relatively large tumours
were present did not regenerate functional lung architecture. This
could be the result of killing of the blood vessel cells, depriving
the tumour cells of nutrients and oxygen, although other areas of
the lung where no tumour was present did not show necrotic cells
in this time frame.
The mechanism of antivascular therapy with immunotoxins
(Burrows and Thorpe, 1994) or with tissue factor (Huang et al,
1997) was shown to be infarction of tumours due to loss of blood
supply. In the current work, targeting was to normal vessels in
lung. Since the lung continued functioning for months after treat-
ment, the tumour in the treated lung should have had some blood
supply. It is possible that lung vessels are repaired from a reposi-
tory of endothelial stem cells which avoid damage by the treat-
ment. Thus, temporary or partial damage to the blood vessels may
have a more dramatic effect on tumour cells than on the normal
lung cells. We have not been able to demonstrate increased
vascular permeability in lung vessels serving tumours following
treatment with 213Bi–mAb 201B (data not shown). Given these
facts, it is likely that the mechanism of therapy included killing of
a significant fraction of tumour cells by a-particles in addition to
any affects due to blood vessel damage.
Larger tumours (1–3 mm) were examined early after treatment
to determine if the range of cell killing (from the blood vessel)
correlated with the a-particle range of 6–10 cell diameters. Cells
in larger tumours became necrotic, but it was not clear which cells
actually survived and went on to progressive growth, or if the
residual live cells originated from areas of the tumour outside of
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‘kill zone’ around the blood vessel in EMT-6 tumours of various
sizes. Neither stains for apoptotic cells nor for tumour cell
membrane were adequate to distinguish dead from live cells, up to
7 days after treatment.
Evidence indicated that a functional immune response was
necessary to effect cures. EMT-6 is immunogenic in the BALB/c
host (Korbelik et al, 1996) and the 213Bi–mAb 201B-treated EMT-
6 lung tumours were completely cured. Treatment of EMT-6 in
SCID mice resulted in tumour growth remissions, but not cures,
indicating that viable tumour cells remained and grew. Line 1
cells, which are very weakly immunogenic (Yuhas et al, 1975),
exhibited residual cells in BALB/c mice which eventually grew
back, analogous to the result for the EMT-6 cell system in SCID
mice. Similarly, all other tumours, IC-12, A431, and A549, treated
in SCID mice regressed, but residual cells ultimately grew to kill
the animals. In summary, complete eradication of tumour cells
apparently did not occur (at least at doses < 7.4 MBq) and a func-
tional immune system was necessary to deal with residual viable
tumour cells.
The rat IC-12 tumour, as well as the human A431 and A549
tumours, represented models of slower growing tumours. The IC-
12 tumour grew perivascularly (Figure 2) similar to the pattern for
EMT-6 tumours. The lifespan of SCID mice bearing IC-12
tumours was significantly extended by treatment with 213Bi–mAb
201B, but the animals eventually developed lung tumours. Both
human tumours grew more slowly, not developing a lethal tumour
burden until about 60 days after i.v. injection. Specific treatment of
animals in these models did not result in increased lifespan, but a
reduction of tumour colonies was observed in both. The data indi-
cate that even slow growing tumours can be killed by the a-
particle irradiation localized in the adjacent vessels as discussed
previously.
Unfortunately, treatment with 213Bi–mAb 201B resulted in
damage to normal lung. BALB/c mice treated with 2.6 MBq doses
develop lung fibrosis at about 100 days post-treatment.
Dose–response data show that animals treated with lower doses
developed damage later. A 2.6 MBq dose cured virtually all of the
EMT-6 lung tumours, while fibrosis developed at day 130 or later.
A dose of 0.925 MBq cured only a few animals of all lung
tumours, but fibrosis did not develop in the cured animals
observed for up to 1 year. Attempts to minimize lung damage by
delivering the dose in fractions, at 3-day intervals, were not as
successful in tumour therapy. The 3-day interval should allow for
some endothelium (Speidel et al, 1993) and epithelium regenera-
tion (Adamson et al, 1977). The EMT-6 tumours grew so fast that
regrowth in the 3-day interval overcame the therapeutic effect of
subsequent fractioned doses. For the EMT-6 model, shorter times
between treatments are likely necessary to combat tumour
regrowth. Fractionated dose therapy of slower growing tumours
may be effective with intervals of 3 days or more. These experi-
ments, as well as other approaches to inhibit the fibrotic response,
are in progress.
CONCLUSION
The experimental results described here are for a model system
designed to investigate the efficacy and mechanism of vascular
targeted a-particle mediated therapy of micrometastases. The data
show that significant, specific tumour cell destruction can be
accomplished from an a-particle source located in vessels adjacent
to the tumour cells. The mechanism of destruction remains
unproven but is likely to involve destruction of tumour cells rather
than, or in addition to, partial interruption of blood supply. Direct
application of lung targeting for treatment of human disease
remains problematic. Tumours confined solely to the lung would
be the only application, and protection from the collateral normal
lung damage would need to be developed. The successful therapy
in this murine model systems adds impetus to efforts to identify
targets selectively expressed in tumour vasculature (Burrows et al,
1995; Epstein et al, 1995; Pasqualini and Ruoslahti, 1996). Once
the correct targeting agents are found, vascular targeting of 213Bi
for therapy of micrometastasis will be an attractive option.
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